MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Bio-Rad Laboratories Inc

Chiusa

SettoreSettore sanitario

247.81 2.67

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

235.85

Massimo

253.96

Metriche Chiave

By Trading Economics

Entrata

780M

64M

Vendite

-82M

585M

EPS

2.54

Margine di Profitto

10.933

Dipendenti

7,700

EBITDA

75M

134M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+33.23% upside

Dividendi

By Dow Jones

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

64M

6.6B

Apertura precedente

245.14

Chiusura precedente

247.81

Notizie sul Sentiment di mercato

By Acuity

50%

50%

163 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Bio-Rad Laboratories Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 lug 2025, 23:09 UTC

Utili

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 lug 2025, 19:16 UTC

Acquisizioni, Fusioni, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 lug 2025, 23:47 UTC

Discorsi di Mercato

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 lug 2025, 23:41 UTC

Discorsi di Mercato

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 lug 2025, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 lug 2025, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 lug 2025, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

James Hardie Completes Acquisition of AZEK

1 lug 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 lug 2025, 20:24 UTC

Utili

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 lug 2025, 19:55 UTC

Discorsi di Mercato

Oil Futures Resume Cautious Rally -- Market Talk

1 lug 2025, 19:27 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 lug 2025, 19:12 UTC

Discorsi di Mercato

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 lug 2025, 19:01 UTC

Acquisizioni, Fusioni, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 lug 2025, 18:41 UTC

Acquisizioni, Fusioni, Takeovers

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 lug 2025, 18:33 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

1 lug 2025, 18:33 UTC

Discorsi di Mercato

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 lug 2025, 18:32 UTC

Discorsi di Mercato

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 lug 2025, 18:22 UTC

Discorsi di Mercato

Remittances to Mexico Down in May -- Market Talk

1 lug 2025, 17:45 UTC

Discorsi di Mercato

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 lug 2025, 17:01 UTC

Acquisizioni, Fusioni, Takeovers

Danone Completed Acquisition of Majority Stake in Kate Farms

1 lug 2025, 16:55 UTC

Utili

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 lug 2025, 16:27 UTC

Discorsi di Mercato

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 lug 2025, 16:25 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 lug 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 lug 2025, 15:48 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 lug 2025, 15:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

1 lug 2025, 15:46 UTC

Discorsi di Mercato

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 lug 2025, 14:54 UTC

Discorsi di Mercato

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 lug 2025, 14:49 UTC

Discorsi di Mercato

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Confronto tra pari

Modifica del prezzo

Bio-Rad Laboratories Inc Previsione

Obiettivo di Prezzo

By TipRanks

33.23% in crescita

Previsioni per 12 mesi

Media 321.5 USD  33.23%

Alto 381 USD

Basso 245 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bio-Rad Laboratories Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

229.835 / 235.8095Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

163 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.